Mirdametinib (PD-0325901) oral capsule or dispersible tablet

Phase 2

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Mirdametinib (PD-0325901) oral capsule or dispersible tablet is one of 19 therapeutic programs targeting Plexiform Neurofibroma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Plexiform NeurofibromaActive, not recruiting

Plexiform NeurofibromaPhase 2

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Plexiform Neurofibroma

#DrugCompanyPhaseTrials

Koselugo

AstraZeneca

Phase 3

4 2

Mekinist

Novartis

Phase 2

2 3

Trexall

Alnylam Pharmaceuticals

Phase 2

1 4

Gleevec

Novartis

Phase 2

1 5

Afinitor

Novartis

Phase 2

1 6

Velban

Eli Lilly

Phase 2

1 7

Mektovi

Pfizer

Phase 2

1 8

Tafinlar

Novartis

Phase 2

1 9

PEG-Intron

Merck & Co.

Phase 2

—10

Esbriet

LLegacy Health System

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Plexiform Neurofibroma

NCT03962543

Clinical

Trials by Indication[1]

Plexiform Neurofibroma1 trial

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity

Active, not recruiting·SSpringWorks Therapeutics, Inc.·Phase 2·NCT03962543·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mirdametinib (PD-0325901) oral capsule or dispersible tablet. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mirdametinib (PD-0325901) oral capsule or dispersible tablet. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Mirdametinib (PD-0325901) oral capsule or dispersible tablet

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Plexiform Neurofibroma1 trial

References

Drug Info

Quick Facts

Related News